Interwest Venture Management Co. Invests $13,579,000 in Applied Genetic Technologies Corporation (AGTC)

Interwest Venture Management Co. bought a new stake in Applied Genetic Technologies Corporation (NASDAQ:AGTC) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,452,216 shares of the company’s stock, valued at approximately $13,579,000. Applied Genetic Technologies Corporation accounts for about 3.2% of Interwest Venture Management Co.’s portfolio, making the stock its 7th largest position. Interwest Venture Management Co. owned 8.04% of Applied Genetic Technologies Corporation as of its most recent filing with the SEC.

A number of other large investors have also bought and sold shares of the company. ClariVest Asset Management LLC purchased a new position in Applied Genetic Technologies Corporation during the third quarter valued at approximately $204,000. Wells Fargo & Company MN raised its position in Applied Genetic Technologies Corporation by 290.2% in the third quarter. Wells Fargo & Company MN now owns 20,936 shares of the company’s stock valued at $205,000 after buying an additional 15,570 shares during the period. Acrospire Investment Management LLC raised its position in Applied Genetic Technologies Corporation by 48.9% in the third quarter. Acrospire Investment Management LLC now owns 23,743 shares of the company’s stock valued at $232,000 after buying an additional 7,800 shares during the period. Smith Asset Management Group LP raised its position in Applied Genetic Technologies Corporation by 2.1% in the third quarter. Smith Asset Management Group LP now owns 25,720 shares of the company’s stock valued at $252,000 after buying an additional 520 shares during the period. Finally, Bank of Montreal Can raised its position in Applied Genetic Technologies Corporation by 3.8% in the third quarter. Bank of Montreal Can now owns 41,580 shares of the company’s stock valued at $406,000 after buying an additional 1,514 shares during the period. Hedge funds and other institutional investors own 56.91% of the company’s stock.

Institutional Ownership by Quarter for Applied Genetic Technologies Corporation (NASDAQ:AGTC)

Applied Genetic Technologies Corporation (NASDAQ:AGTC) traded down 2.05% on Monday, hitting $7.15. The stock had a trading volume of 232,459 shares. The company’s 50 day moving average price is $8.52 and its 200-day moving average price is $10.18. Applied Genetic Technologies Corporation has a 12-month low of $6.07 and a 12-month high of $19.86. The company has a market cap of $129.17 million, a price-to-earnings ratio of 12.43 and a beta of 1.69.

Applied Genetic Technologies Corporation (NASDAQ:AGTC) last issued its earnings results on Wednesday, February 8th. The company reported $0.11 EPS for the quarter, beating the consensus estimate of $0.02 by $0.09. The company earned $10.90 million during the quarter, compared to analysts’ expectations of $11.10 million. Applied Genetic Technologies Corporation had a net margin of 22.20% and a return on equity of 9.32%. The business’s revenue for the quarter was down 10.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.17 EPS. Equities research analysts anticipate that Applied Genetic Technologies Corporation will post $0.47 EPS for the current year.

This article was published by sleekmoney and is the property of of sleekmoney. If you are accessing this article on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark law. The original version of this article can be read at http://sleekmoney.com/interwest-venture-management-co-invests-13579000-in-applied-genetic-technologies-corporation-agtc/1658915.html.

Several research firms have commented on AGTC. Zacks Investment Research raised Applied Genetic Technologies Corporation from a “hold” rating to a “buy” rating and set a $7.75 price target on the stock in a research report on Friday. Roth Capital raised Applied Genetic Technologies Corporation from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $12.00 to $15.00 in a research report on Wednesday, November 9th. Wedbush reaffirmed an “outperform” rating and set a $17.00 price target (down previously from $20.00) on shares of Applied Genetic Technologies Corporation in a research report on Wednesday, November 9th. Cantor Fitzgerald set a $15.00 price target on Applied Genetic Technologies Corporation and gave the stock a “hold” rating in a research report on Wednesday, February 8th. Finally, Stifel Nicolaus cut their price target on Applied Genetic Technologies Corporation from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Applied Genetic Technologies Corporation currently has an average rating of “Buy” and an average target price of $13.68.

In other news, Director Ivana Magovcevic acquired 3,000 shares of the stock in a transaction that occurred on Wednesday, November 16th. The stock was acquired at an average price of $9.63 per share, for a total transaction of $28,890.00. Following the transaction, the director now directly owns 3,000 shares in the company, valued at $28,890. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.46% of the stock is owned by corporate insiders.

Applied Genetic Technologies Corporation Company Profile

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

5 Day Chart for NASDAQ:AGTC

Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Corporation (NASDAQ:AGTC).

This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/interwest-venture-management-co-invests-13579000-in-applied-genetic-technologies-corporation-agtc/1658915.html

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

 

Leave a Reply

Your email address will not be published. Required fields are marked *